Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia

被引:88
作者
Fröhling, S [1 ]
Skelin, S [1 ]
Liebisch, C [1 ]
Scholl, C [1 ]
Schlenk, RF [1 ]
Döhner, H [1 ]
Döhner, K [1 ]
机构
[1] Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany
关键词
D O I
10.1200/JCO.2002.08.155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To prospectively compare cytogenetic and molecular cytogenetic analysis for the detection of the most relevant chromosome abnormalities in a large series of patients with acute myeloid leukemic (AML). Patients and Methods: Two hundred forty consecutive adult patients with AML entered onto the multicenter treatment trial AML HD93 were studied. Chromosome banding and fluorescence in situ hybridization (FISH) applying a comprehensive set of genomic DNA probes were performed in a single reference laboratory. Results: Two cases of inv(16), three cases of t(11q23), and three cases of t(8;21)var were only detected by molecular cytogenetics. By FISH, aberrations were identified in three cases with normal karyotypes: inv(16), -Y (in a patient with low metaphase yield on chromosome banding) and a 12p microdeletion. Additional aneuploiclies, in particular +8q and +11q, were diagnosed by FISH; however, virtually all these aberrations occurred in patients with complex karyotypes or as an additional abnormality in leukemias with an AML-specific translocation. Finally, aberrations were detected by FISH in eight of 14 patients with no assessable metaphases. Conclusion: In most cases of AML, conventional cytogenetic study reliably detects chromosomal abnormalities, and this method should not be replaced by FISH. FISH should be used as a complementary method for the detection of more subtle abnormalities, such as inv(16) and t(11q23), in all patients with newly diagnosed ANIL and for suspected t(8;21)var. Furthermore, molecular cytogenetics using this comprehensive set of DNA probes provides a valuable diagnostic too[ for patients with poor chromosome morphology, low or no yields of metaphase cells, or both. (C) 2002 by American Society of Clinical Oncology.
引用
收藏
页码:2480 / 2485
页数:6
相关论文
共 23 条
[11]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[12]  
Kiyoi H, 1999, BLOOD, V93, P3074
[13]  
LENGAUER C, 1992, CANCER RES, V52, P2590
[14]  
Mitelman F., 1995, SUPPLEMENT INT SYSTE
[15]   Clinical importance of cytogenetics in acute myeloid leukaemia [J].
Mrózek, K ;
Heinonen, K ;
Bloomfield, CD .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2001, 14 (01) :19-47
[16]  
Mrozek K, 1997, SEMIN ONCOL, V24, P17
[17]   Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia:: A cancer and leukemia group B study [J].
Mrózek, K ;
Prior, TW ;
Edwards, C ;
Marcucci, G ;
Carroll, AJ ;
Snyder, PJ ;
Koduru, PRK ;
Theil, KS ;
Pettenati, MJ ;
Archer, KJ ;
Caligiuri, MA ;
Vardiman, JW ;
Kolitz, JE ;
Larson, RA ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2482-2492
[18]  
Mrozek K, 1997, BLOOD, V90, P4532
[19]   Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia [J].
Pabst, T ;
Mueller, BU ;
Zhang, P ;
Radomska, HS ;
Narravula, S ;
Schnittger, S ;
Behre, G ;
Hiddemann, W ;
Tenen, DG .
NATURE GENETICS, 2001, 27 (03) :263-270
[20]   SELECTION OF A HUMAN CHROMOSOME-21 ENRICHED YAC SUB-LIBRARY USING A CHROMOSOME-SPECIFIC COMPOSITE PROBE [J].
ROSS, MT ;
NIZETIC, D ;
NGUYEN, C ;
KNIGHTS, C ;
VATCHEVA, R ;
BURDEN, N ;
DOUGLAS, C ;
ZEHETNER, G ;
WARD, DC ;
BALDINI, A ;
LEHRACH, H .
NATURE GENETICS, 1992, 1 (04) :284-290